Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) Stock Price

RANIStock

$0.89+40.87%52W

Market Cap$125.20M

P/E—

PEG Ratio—

Div yield—

Beta0.77

RANI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-43.63%

Price vs S&P 500 (4W)4.23%

VGM Score55.12

Book Value / Share (Quarterly)$0.23

P/TBV (Annual)2.73x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-15.64%

Cash Flow / Share (Quarterly)$-0.14

Price vs S&P 500 (YTD)-46.85%

Net Profit Margin (TTM)-547.11%

EPS (TTM)$-0.41

10-Day Avg Trading Volume0.85M

EPS Excl Extra (TTM)$-0.41

Revenue Growth (5Y)10.75%

EPS (Annual)$-0.45

ROI (Annual)-89.89%

Net Profit Margin (5Y Avg)-2277.42%

Cash / Share (Quarterly)$0.35

Revenue Growth QoQ (YoY)893.02%

ROA (Last FY)-50.62%

Revenue Growth TTM (YoY)164.08%

EBITD / Share (TTM)$-0.33

ROE (5Y Avg)-392.26%

Operating Margin (TTM)-550.65%

Cash Flow / Share (Annual)$-0.15

P/B Ratio3.83x

P/B Ratio (Quarterly)3.20x

Net Income / Employee (Annual)$-430,000

EV / Revenue (TTM)31.29x

Net Interest Coverage (TTM)-18.84x

ROA (TTM)-85.63%

EPS Incl Extra (Annual)$-0.45

Current Ratio (Annual)4.21x

Quick Ratio (Quarterly)3.30x

3-Month Avg Trading Volume0.90M

52-Week Price Return40.87%

Revenue / Employee (TTM)$45,900

Tangible BV / Share (Quarterly)$0.35

P/S Ratio (Annual)66.63x

Asset Turnover (Annual)0.03x

52-Week High$3.87

Operating Margin (5Y Avg)-3169.63%

EPS Excl Extra (Annual)$-0.45

CapEx CAGR (5Y)-40.70%

26-Week Price Return-32.38%

Quick Ratio (Annual)4.08x

13-Week Price Return-17.85%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.40x

Enterprise Value$99.16M

Revenue / Share Growth (5Y)3.90%

Asset Turnover (TTM)0.06x

Revenue / Employee (Annual)$23,700

Pretax Margin (Annual)-2507.65%

Cash / Share (Annual)$0.41

3-Month Return Std Dev85.16%

Net Income / Employee (TTM)$-426,700

ROE (Last FY)-89.89%

Net Interest Coverage (Annual)-15.61x

EPS Basic Excl Extra (Annual)$-0.45

Receivables Turnover (TTM)2.40x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.41

ROI (TTM)-56.46%

P/S Ratio (TTM)34.33x

Pretax Margin (5Y Avg)-3259.90%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$0.75

Price vs S&P 500 (52W)22.55%

Year-to-Date Return-34.89%

5-Day Price Return6.49%

EPS Normalized (Annual)$-0.45

ROA (5Y Avg)-45.25%

Net Profit Margin (Annual)-1817.09%

Month-to-Date Return13.55%

Cash Flow / Share (TTM)$-2.79

EBITD / Share (Annual)$-0.57

Operating Margin (Annual)-2381.26%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-69.41%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.41

P/TBV (Quarterly)5.73x

P/B Ratio (Annual)4.97x

Pretax Margin (TTM)-539.26%

Book Value / Share (Annual)$0.27

Price vs S&P 500 (13W)-20.64%

Beta0.77x

Revenue / Share (TTM)$0.02

ROE (TTM)-56.46%

52-Week Low$0.44

vGradeD

gGradeA

mGradeC

vgmGradeC

RANI Earnings Surprise History

Q2 25-0.18est. -0.20

Q3 25-0.12est. -0.12

Q4 25-0.07est. -0.07

Q1 26-0.04est. -0.04

Q2 26-0.04est. -0.05

RANI Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
RANIRani Therapeutics Holdings, Inc. Class A Common Stock	D	A	C	$0.89
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Rani Therapeutics Holdings, Inc. Class A Common Stock

Rani Therapeutics is a clinical-stage biotherapeutics company developing the RaniPill platform to deliver biologics such as antibodies, proteins, peptides, and oligonucleotides orally instead of by injection. The proprietary technology aims to provide patients and healthcare systems with a more convenient alternative to painful subcutaneous or intravenous injections. The company is also advancing RaniPill HC to enable delivery of liquid drug payloads with high bioavailability.